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Progressive cardiomyopathic lentiginosis. 
Note 
LEOPARD syndrome is characterized by multiple 
lentigines, cardiac anomalies, facial dysmorphisms, 
abnormalities of the genitalia in males, retardation of 
growth, and deafness. LEOPARD syndrome shares 
many features with Noonan syndrome, in which 
lentigines and deafness usually are not present. 
Molecular studies have demonstrated that LEOPARD 
and Noonan syndromes are allelic conditions. 
Inheritance 
LEOPARD syndrome is an autosomal dominant 
multiple congenital anomaly syndrome, with high 
penetrance and markedly variable expression. 
Clinics 
Phenotype and clinics 
The main clinical features of LEOPARD syndrome are 
multiple lentigines, congenital heart defect or 
electrocardiographic abnormalities, deafness, facial 
anomalies, urogenital malformations, skeletal 
anomalies, retardation of growth, and learning 
difficulties. 
Diffuse lentiginosis is a characteristic of LEOPARD 
syndrome. Lentigines are brown macules, usually 2 to 8 
mm in diameter, generally most heavily concentrated 
on the upper part of the trunk and neck, although they 
can also be present on the face, limbs, palms, soles and 
genitalia. The mucosae are characteristically spared. 
Lentigines are rarely present at birth and, classiclly, 
develop during childhood, increasing in number until 
puberty and darkening with age. Cafe-au lait patches as 
well as axillary freckling have also been described. 
Structural cardiac defects can be detected in 70% of the 
patients. Hypertrophic cardiomyopathy is the most 
common defect. It is progressive and commonly 
involves the intraventricular septum. Pulmonary valve 
stenosis with valve leaflet dysplasia, partial 
atrioventricular canal and mitral valve anomalies can 
also be present. Arrhythmias include heart block, 
bundle branch block, and hemiblock. 
Deafness is generally sensorineural, may be unilateral, 
but can be profound. Most cases have deafness 
diagnosed in childhood, but some are reported to have 
developed it in adult life. 
Facial anomalies include hypertelorism, palpebral 
ptosis, and large low-set ears. They occur in 90% of the 
patients. 
A high prevalence of genitourinary abnormalities has 
been reported especially in male patients. These include 
cryptorchidism, hypospadias, as well as malformations 
of the kidneys and collecting systems. 
Pectus carinatum or excavatum are detectable. In old 
age, there is a tendency to develop thoracic kyphosis. 
Growth retardation is frequent. The adult height is 
generally below the 25th centile. 
Mild mental retardation and learning difficulties, so as 
language defects related to deafness, can occur in 
patients with LEOPARD syndrome. 










Legend: Typical multiple lentigines in a patient with LEOPARD syndrome. 
 
Neoplastic risk 
A distinct class of somatic mutations of PTPN11, 
appearing to have high gain-of-function levels, 
contributes to leukemogenesis. The identification of 
these mutations at a germinal level explains the higher 
prevalence of myeloproliferative disorders and acute 
leukemia among children with Noonan or LEOPARD 
syndrome. The RAS/MAPK pathway is deregulated in 
juvenile myelomonocytic leukemia due to mutations i 
NRAS, KRAS2 or NF1. It has be hypothesized that 
germline or somatic mutations in PTPN11 could also 
interfere with RAS/MAPK pathway. 
Multiple granular cell myoblastomas, a tumor believed 
to arise from Schwann cells, have been reported in one 
patient. 
Central giant cell granulomas presenting as cyst-like 
lesions in the mandible have also been described in 
LEOPARD syndrome.  
Choristoma, a congenital corneal tumor containing 
cellular elements of ectodermal derivatives, may 
occasionally coexist with LEOPARD syndrome. 
Treatment 
Beta-blockade or calcium channel blockers are most 
frequently used in treatment of obstructive 
cardiomyopathy. If there is no response to drug 
therapy, surgery for left ventricular outflow obstruction 
or transplantation can be indicated. 
The use of lasers has been shown to be effective in the 
treatment of lentigines. Noninvasive agents such as 
tretinoin cream and hydroquinone cream used in 
combination have been shown to lighten lentigines 
after several months of application. 
Prognosis 
The prognosis is mainly determined by the nature and 
severity of cardiac lesions. In fact, the major concer  is 
that of hypertrophic cardiomyopathy, because of its 
association with arrhythmia and sudden death. 
Cytogenetics 
Note 
Chromosome analysis is normal in patients with 
LEOPARD syndrome. 
Genes involved and proteins 
PTPN11 
Alias 




Description: It contains two Srd homology 2 (SH2) 
domains and a protein tyrosine phosphatase domain 
(PTP); 15 exons. 
Protein 
Description: 593 amino acids, 68 kD. 
Expression: Highly expressed in human tissues, 
particularly abundant in heart, brain, and skeletal 
muscle. 
Function: The protein-tyrosine phosphatases are a 
highly polymorphic set of molecules having a role in 
regulating the responses of eukaryotic cells to 
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extracellular signals. They achieve this by regulating 
the phosphotyrosine content of specific intracellular 
proteins. The pathogenetic mechanism that causes 
PTPN11 mutations to specifically exhibit a 
dermatological phenotype and preferentially cardiac 
expresssion in hypertrophic cardiomyopathy is at 
present unclear. 
Mutations 
Germinal: LEOPARD syndrome has proved to be 
allelic to Noonan syndrome, with two recurrent 
PTPN11 mutations in exons 7 (Tyr279Cys) and 12 
(Thr468Met). Additional mutations in exons 7, 12, and 
13, different from the two common mutation hot spot, 
have been reported as a rare occurrence in the 
syndrome. All the mutations occur in exons that code 
for the protein tyrosine phosphatase (PTP) domain. 
Molecular and biochemical studies have shown that te 
mutations destabilize the catalytically inactive 
conformation of the protein, resulting in a gain of 
function. PTPN11 mutations are detectable in about 
90% of patients with LEOPARD syndrome. 
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